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The selectins, namely E-, P-, and L-se-
lectin, form a family of Ca2+-dependent 
lectins. Upon an inflammatory stimulus, 
E- and P-selectin are upregulated on en-
dothelial cells (E-selectin, P-selectin) and 
platelets (P-selectin). They mediate the 
rolling of leukocytes on the endothelial 
surface, which is followed by firm adhe-
sion via the interaction of integrins with 
members of the super IgG family and trans-
migration to the site of inflammation.[1] 
This process, forming a vital defense 
mechanism in the event of injuries or in-
fections, can turn deleterious in numerous 
diseases with an inflammatory component 
like stroke, reperfusion injury, psoriasis or 
rheumatoid arthritis.[2] Furthermore, se-
lectins are involved in tumor metastasis.[3] 
Therefore, blocking the interaction of se-
lectins with their physiological ligands 
has been recognized as a promising thera-
peutic approach for the therapy of these 
diseases. Consequently, various concepts 
have been applied to disrupt the selectin-
mediated cell–cell interaction, either by 
antagonizing the receptor, by modulating 
selectin expression, or by cleaving selectin 
ligands.[4] This mini-review gives an over-
view on E- and P-selectin antagonists and 
elucidates how their design is guided by 
differences and similarities between E- and 
P-selectin.
2. E- and P-Selectin: Differences 
and Similarities 
The tetrasaccharide sialyl Lewisx (sLex, 
Fig. 1) was identified as the minimal carbo-
hydrate binding epitope recognized by all 
three selectins.[8] The carbohydrate recog-
nition domain (CRD) of E- and P-selectin, 
which is characterized by a Ca2+ ion essen-
tial for sLex binding, is almost identical.[9,10] 
Consequently, similar conformations of sLex 
bound to P- and E-selectin were found.[10,11] 
Besides the CRD for sLex, P-selectin of-
fers a second, structurally and operation-
ally distinct binding site not present on 
E-selectin.[12] This second site is rich in 
positively charged amino acid side chains 
and therefore allows binding of a broad 
range of negatively charged biopolymers 
(section 4). The natural ligand of P-selec-
tin, P-selectin glycoprotein ligand 1 (PS-
GL-1), binds to both sites, the CRD and the 
polyanion binding site, simultaneously.[10] 
Its binding epitopes include sLex, which 
is essential for recognition,[13] and three 
sulfated tyrosines (Tyr 46, 48, 51), which 
are vital for high binding affinity (Fig. 
2).[10,14,15] When these two binding epitopes 
are combined, a synergistic effect[12] leads 
to an approximately 10’000-fold improved 
binding of PSGL-1 compared to sLex.[11,16] 
The existence of a second binding site 
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two of their compounds efficiently blocked 
leukocyte rolling in vivo (e.g. 8, Fig. 5). 
Girard et al. reported IC
50
 values in the mil-
limolar range in a cell-based competitive 
binding assay for their P- and E-selectin 
antagonists (e.g. 9, Fig. 5).[27] Research-
ers at Wyeth identified quinoline salicylic 
acids as promising P-selectin antagonists 
via high-throughput screening.[28] The lead 
compound PSI-697 (10)[29] is currently in 
Phase I clinical trials and the follow-up 
PSI-421 (11)[30] has reached the prede-
velopment stage. Finally, Schön et al. re-
ported on the macrolide efomycine M (12) 
as a potent selectin antagonist mimicking 
sLex.[31] Though the exact binding mode is 
still being discussed controversially,[32] it 
is interesting to note that efomycine M sig-
nificantly reduced leukocyte rolling in vivo 
and alleviated cutaneous inflammation in 
two mouse models of psoriasis. 
4. Polyanions 
Numerous polyanions like sulfa-
tides,[33] heparin,[34] lipopolysaccharides 
(LPS),[35] fucoidin, sulfated dextran,[36] 
chondroitin sulfate,[37] dermatan sulfate,[38] 
and sulfated hyaluronic acid[39] have been 
reported to exhibit P-selectin antagonism. 
The broad range of charged compounds 
lacking the carbohydrate epitope suggests 
tions on the design of P-selectin antago-
nists. According to the addressed binding 
sites, P-selectin antagonists are divided in-
to three groups: mimetics of sLex (section 
3), polyanions (section 4), and mimetics of 
PSGL-1 (section 5).
3. Mimetics of sLex 
Since sLex is the common binding epit-
ope recognized by all three selectins, it has 
served as starting point for numerous drug 
discovery programs. The tetrasaccharide 
itself suffers from the typical downsides 
of carbohydrates, which are the poor phar-
macokinetic and pharmacodynamic prop-
erties as well as complex synthesis, and 
therefore ultimately failed as drug candi-
date.[17] In consequence, efforts were pri-
marily directed to reduce the carbohydrate 
character while enhancing affinity and 
conserving the pharmacophore (Fig. 1). 
The search for high affinity-antago-
nists followed two major strategies. In a 
first approach, the carbohydrate moieties 
were systematically replaced with mimet-
ics containing the relevant pharmacoph-
oric groups. In a second approach, antago-
nists were rationally designed based on 
the pharmacophore of sLex. Furthermore, 
database screening with the 3D phar-
macophore of sLex and high throughput 
screening yielded additional leads. Since 
the resulting antagonists up to 2002 are 
covered by several excellent reviews,[17,18] 
only two representative examples of that 
period are discussed here. Following the 
first strategy, a group at Ciba and later at 
Novartis replaced the sialic acid moiety 
of sLex by S-cyclohexyl lactic acid and 
the N-acetyl glucosamine unit with R,R-
1,2-cyclohexanediol. The resulting lead 
CGP69669A (2)[19] was further developed 
by Glycomimetics Inc. to the pan-selectin 
antagonist GMI-1070 (3)[20] which is now 
in Phase II clinical trials for the treatment 
of sickle cell crisis (Fig. 3). Kogan et al. 
applied the second strategy to design a se-
ries of biphenyl-based inhibitors mimick-
ing the hydroxyl groups of l-fucose with 
d-mannose and the carboxylic acid residue 
of sialic acid.[21] TBC265 (4, Fig. 4) shows 
affinity for E-, P-, and L-selectin. Its dimer 
TBC1269 (5)[22] is currently in Phase II 
clinical trials for treatment of asthma and 
psoriasis.
Recently published selectin antago-
nists exemplify a clear trend to compounds 
lacking any carbohydrate moiety. Kranich 
et al. used TBC1269 (5) as template for the 
rational design of a series of nonglycosid-
ic, nonpeptidic, polyphenolic pan-selectin 
antagonists, e.g. 6 in Fig. 5.[23] For the best 
representatives, low micromolar affinities 
in a static cell free assay and significant 
inhibition of HL-60 cell attachment to se-
lectins under flow conditions are reported. 
Although initially designed to mimic sLex, 
the authors also consider the possibility 
of alternative binding modes. Based on a 
pharmacophore model originally devel-
oped by the Kondo group,[24] Ulbrich et al. 
recently developed pan-selectin inhibitors 
with two carboxylates and a hydrophobic 
tail (e.g. 7, Fig. 5).[25] They propose that 
one carboxylate coordinates to Ca2+ and 
the second one forms a salt bridge to Arg97 
of E-selectin or Lys99 of P-selectin. The 
long alkyl chains are considered to interact 
with hydrophobic regions of the selectins. 
Although the authors claim the absence 
of micelles at concentrations equal to the 
IC
50
, the antagonists obviously resemble 
detergents. Therefore, multivalency due 
to micelle formation or simply unspecific 
lipophilic interactions might be the reason 
for their affinity. This hypothesis is sup-
ported by the fact that total loss of affinity 
was reported for compounds lacking the 
hydrophobic tail. The groups of Kaila and 
Girard independently reported on quinic 
acid derivatives mimicking sLex, e.g. 8[26] 
and 9[27] (Fig. 5). Their hypothesis that 
quinic acid mimics fucose and coordinates 
to Ca2+ was confirmed by a crystal struc-
ture of quinic acid in complex with E-se-
lectin.[26] Kaila and coworkers found only 
low affinities for their compounds in a sur-
face plasmon resonance assay. However, 
Fig. 3. E-selectin antagonist CGP69669A (2) and pan-selectin antagonist GMI-1070 (3).
Fig. 4. TBC265 (4) and its dimer TBC1269 (5).
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sulfates alone.[47] Smaller fragments mim-
icking the binding epitopes on PSGL-1 
have also been assembled successfully on 
nanoparticles.[44,48] Since monovalent frag-
ments show no significant inhibitory effect 
on P-selectin binding, the affinity of these 
nanoparticles was suggested to result from 
multivalency.
6. Conclusion and Outlook
E- and P-selectin share a high degree 
of similarity in their CRDs. Numerous an-
tagonists that target these binding sites by 
mimicking sLex have been developed, and 
the successful performance of several of 
these antagonists in preclinical and clinical 
tests convincingly prove that small mole-
cules are indeed suited as selectin antago-
nists. Finally, small molecules occupying 
both binding sites of P-selectin potentially 
offer increased affinity and selectivity and 
might fill an important gap in the therapy 
with selectin antagonists.
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